# A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease

> **NCT05286853** · PHASE3 · WITHDRAWN · sponsor: **Prokidney**

## Conditions studied

- Type 2 Diabetes Mellitus
- Chronic Kidney Diseases

## Interventions

- **BIOLOGICAL:** Renal Autologous Cell Therapy (REACT)
- **PROCEDURE:** Sham Comparator

## Key facts

- **NCT ID:** NCT05286853
- **Lead sponsor:** Prokidney
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-07-17
- **Primary completion:** 2024-09-03
- **Final completion:** 2024-09-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Rilparencel is eligible for initial FDA/ RMAT approval pathway upon successful completion Phase3 REGEN006 (PROACT1) trial. Discontinued Phase3 REGEN016 (PROACT2) focused on enrollment outside the US and is not required for initial US registration.
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286853, "A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05286853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*